Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Buy at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research report released on Monday.

Several other analysts also recently issued reports on the stock. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a peer perform rating for the company. Chardan Capital reduced their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a buy rating for the company in a research report on Friday, February 16th. Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating on the stock in a report on Friday, February 16th. Needham & Company LLC reaffirmed a buy rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Finally, Citigroup cut their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating on the stock in a report on Friday, February 16th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $215.88.

Alnylam Pharmaceuticals Trading Up 4.2 %

NASDAQ:ALNY opened at $149.96 on Monday. The company has a fifty day moving average of $150.11 and a 200-day moving average of $165.46. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same period in the previous year, the business posted ($1.68) EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -4.46 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Quent Capital LLC raised its stake in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the period. Anchor Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $38,000. GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $52,000. Finally, V Square Quantitative Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $52,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.